Prelude Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Prelude Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$97K	–	2200
2022 Q1	$97K	Hold	10,000	–	–	﹤0.01%	1428
2021 Q4	$97K	Hold	10,000	–	–	﹤0.01%	1731
2021 Q3	$97K	Hold	10,000	–	–	﹤0.01%	1512
2021 Q2	$97K	Buy	+10,000	New	+$98.2K	﹤0.01%	1477

Other funds holding EBAC

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Prelude Capital Management's EBAC Position: Q2 2022 in Review

Prelude Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q2 2022, closing a stake of 10,000 shares — an estimated $97K sold.

Prelude Capital Management first reported a position in EBAC in Q2 2021 and held it in 4 quarters. The position peaked at $97K in Q1 2022. 46 funds tracked by Wall St. Rank hold EBAC as of Q2 2022.

Prelude Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Prelude Capital Management sold 10,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q2 2022, an estimated $97K.
Prelude Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 4 quarters.
Prelude Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $97K in Q1 2022.
46 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.